Xenetic Biosciences, Inc. carries no debt; cash flow comfortably covers obligations.

Xenetic Biosciences, Inc.'s free cash flow has increased -18.84% from $-2.82M last year to $-2.29M, signaling increasing performance

Xenetic Biosciences, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Xenetic Biosciences, Inc. has insufficient data to evaluate this check.

Xenetic Biosciences, Inc. has negative EBITDA, making leverage ratio unreliable

Xenetic Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Xenetic Biosciences, Inc.'s profit margin has increased (-55.79%) in the last year from -158.39% to -70.03%, signaling increasing performance

Xenetic Biosciences, Inc.'s short-term assets of $8.05M exceed its short-term liabilities of $968.02K

Xenetic Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Xenetic Biosciences, Inc.'s return on equity of -39.28%, is lower than 15.00%, indicating bad performance

Xenetic Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Xenetic Biosciences, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Xenetic Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Xenetic Biosciences, Inc. has negative free cash flow, indicating cash burn

Xenetic Biosciences, Inc.'s yearly earnings has increased -32.31% since last year from $-3.96M to $-2.68M, signaling increasing performance

Xenetic Biosciences, Inc.'s yearly revenue has increased 19.04% since last year from $2.50M to $2.98M, signaling increasing performance

ROIC -34.45% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Xenetic Biosciences, Inc.'s 3-year revenue CAGR of 20.36% is positive, indicating growing revenue over the past 3 years

Xenetic Biosciences, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Xenetic Biosciences, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Xenetic Biosciences, Inc. has insufficient data to evaluate this check.

Xenetic Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Xenetic Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Xenetic Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Xenetic Biosciences, Inc. has insufficient data to evaluate this check.

Xenetic Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Xenetic Biosciences, Inc. has a price-to-book ratio of 0.99x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Xenetic Biosciences, Inc. has a price-to-sales ratio of 2.15x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue